COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
Chase Therapeutics translates neuroscience into CNS therapies, advancing CTC-413 for Parkinson’s and CTC-501 for major depressive disorder into Phase 3 and developing a companion diagnostic for earlier Parkinson’s detection.
